All In Biotech

Drug Trial Radar · NCT06436742

A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)

A Phase 1b, Double-Blinded, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Efficacy of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes

Last checked: Nov 19, 2026Latest source record: Jul 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

15

Actual

Start

Sep 24, 2024

Primary completion

Aug 24, 2027

Study completion Jan 24, 2028

Sponsor

Lead sponsor
argenxargenx (ARGX)
Sponsor type
Industry
First posted
May 31, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and tolerability of ARGX-119 in adult participants with DOK7- Congenital Myasthenic Syndromes. The study will also assess how ARGX-119 is processed by the body (pharmacokinetics), how the immune system reacts to it (immunogenicity), and how it may improve the way patients feel and function. After the screening period, eligible participants will be randomized in a 4:1 ratio to receive intravenous infusions of ARGX-119 or placebo during the double-blinded treatment period. Participants will then enter the follow-up period. After the follow-up period, participants may enrol in the active-treatment period, where they will receive open-label ARGX-119. The full duration of the study is approximately 38 months.

Conditions

  • Congenital Myasthenic Syndrome
  • CMS

Interventions

  • ARGX-119Biological

    Intravenous infusion of ARGX-119

  • PlaceboOther

    Intravenous infusion of placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assessment of adverse events (AEs)Time frame: Up to week 42
  2. Change from active-treatment baseline over time for 6MWT distanceTime frame: Up to 72 weeks

Locations

9 sites in 6 countries. Site status is shown where the registry gives one.

  • UC Davis Medical Center

    Sacramento, California

  • Ann and Robert H Lurie Childrens Hospital of Chicago

    Chicago, Illinois

  • Ottawa Hospital Research Institute - Civic Campus

    Ottawa, Canada

  • CHU - Hospital de la Timone

    Marseille, France

  • Group Hospitalier Pitie-Salpetriere

    Paris, France

  • Fondazione IRCCS Istituto Neurologico Carlo Besta

    Milan, Italy

  • Universitat de Valencia - Hospital Universitari i Politecnic La Fe de Valencia (Hospital La Fe Bulevar Sur)

    Valencia, Spain

  • Clinical Trials Centre - South Eastern Health and Social Care Trust - The Ulster Hospital

    Belfast, United Kingdom

  • John Radcliffe Hospital - Oxford University Hospitals NHS Foundation Trust

    Oxford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.